Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901

Bibliography

• European Association for the Study of the Liver. EASL clinical practice guidelines. J Hepatol 2009;50:227-42.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
   PubMed Web of Science ®Google Scholar
• Lai CL, Dienstag J, Schiff E, Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-95.
   Web of Science ®Google Scholar
• Mazzucco CE, Hamatake RK, Colonno RJ, Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605
   PubMed Web of Science ®Google Scholar
• European medicines Agency Sebivo® Summary of Product Characteristics. Available from: http://www.emea.europa.eu [ Last accessed 16 March 2011]
   Google Scholar
• But DY, Yuen MF, Fung J, Safety evaluation of telbivudine. Expert Opin Drug Saf 2010;9:821-9
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
   PubMed Web of Science ®Google Scholar
• Fisher EJ, Chaloner K, Cohn DL, The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15:1695-700
   PubMed Web of Science ®Google Scholar
• Kahn J, Lagakos S, Wulfsohn M, Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-12
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Launay-Vacher V, Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153-8
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Boyd A, Bottero J, Lascoux-combe C, Significant liver fibrosis is an independent risk factor of renal impairment in HIV-HBV co-infected patients treated with tenofovir (TDF): results of a 3-year-cohort study. Hepatology 2010;52(Suppl 4):513A
   Web of Science ®Google Scholar
• Brodzinski A, Fueloep B, Schlosser B, Prevalence of renal alterations indicative for proximal tubular damage (PTD) in patients with chronic hepatitis B virus infection during long-term treatment with tenofovir disoproxil fumarate (TDF). Hepatology 2010;52(Suppl 1):515A
   Google Scholar
• Chang TT, Lai CL, Kew YS, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Pokornoski KA, Rose RE, Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009;50(Suppl 1):S10
   PubMedGoogle Scholar
• Lai CL, Rosmawati M, Lao J, Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, Hadziyannis SJ, A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT, Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H, Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Shouval D, Lai CL, Chang TT, Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-95
   PubMed Web of Science ®Google Scholar
• Pessoa MG, Gazzard B, Huang AK, Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-87
   PubMed Web of Science ®Google Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Hann HW, Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Hofmann WP, Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
   PubMed Web of Science ®Google Scholar
• Lange CM, Sprinzl K, Vermerhren J, Prospektive Untersuchung von Laktat-Konzentrationen im Blut von Patienten mit chronischer Hepatitis B und dekompensierter Leberzirrhose wahrend der Therapie mit Nukleos(t)id-Analoga. Med Klin 2010;105(Suppl 1):PS 25
   Google Scholar
• Ridruejo E, Adrovar R, Cocozella D, Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 2011; 65:866-70
   PubMed Web of Science ®Google Scholar
• Zoutendijk R, Reijnders JG, Brown A, Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54:443-51
   PubMed Web of Science ®Google Scholar
• Buti M, Morillas RM, Prieto M, A viral load reduction > 3 log at 12 week of Entecavir treatment correlated with HBe seroconversion in HBeag positive patients. Results from a real-life setting study (the ORIENTE study). Hepatology 2010; 52(Suppl 1): abstract 409
   Google Scholar
• Lampertico P, Vigano M, Soffredini R, Maintained long-term suppression of HBV replication in NUC-naive patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicentre experience. Hepatology 2010; 52(Suppl 1): abstract 391
   Google Scholar
• Seto WK, Lai CL, Fung J, Outcome of 4-year treatment of entecavir for treatment-naive chronic hepatitis B. J Hepatol 2011; 54:S301.
   Web of Science ®Google Scholar